Monoclonal antibodies that recognize the extracellular domain of the epidermal growth factor receptor (mAblO8) were conjugated with doxorubicin through a dextran bridge. Several antibody-drug conjugates, containing different amounts of doxorubicin, retained binding capacity to human epidermoid carcinoma (KB) cells overexpressing epidermal growth factor receptors. Slight decrease in drug cytotoxicity was seen in in vitro tests, as determined either by inhibition of thymidine incorporation into cells or by reduction in number and size of KB-cell colonies. Yet, when tested in vivo against KB tumor xenografted into nude mice, the antiepidermal growth factor-receptor drug conjugates with high drug-substitution levels were significantly more effective than free doxorubicin, antibody alone, mixture of dextran-doxorubicin and antibody, or drug conjugated with irrelevant antibody. When the labile covalent bonds linking antibody to dextran bridge were stabilized by reduction, the therapeutic efficacy ofthe conjugate was markedly decreased. These results show that antibodies against the extracellular domain of the epidermal growth factor can deliver doxorubicin specifically and efficiently to tumor sites that express high receptor levels exerting a specific antitumor effect. (8) .
The high toxicity of currently used anticancer drugs dictates a careful balance in treatment schedules between killing the tumor cells and excessive toxicity to the patient. Such considerations often impose administration of doses that are limited in efficiency. The purpose of drug targeting is to deliver the toxic agents selectively to the tumor cells while sparing normal cells. Overexpression of epidermal growth factor (EGF) receptor was found in various types of human cancers, including gliomas and both epidermoid and squamous carcinoma cells (1-7), thus offering a potential recognition site for specific delivery of cytotoxic agents to these tumors. Moreover, the EGF receptor plays an important role in regulating cell growth and oncogenesis and, therefore, blocking this receptor by antibodies may interfere with signal-transduction pathways in addition to cytotoxicity per se. Indeed, we have recently demonstrated that monoclonal antibodies (mAb) against the extracellular domain ofthe EGF receptor (mAblO8) can concentrate on subcutaneous xenografts of KB cells in nude mice and retard cellular growth (8) . The antiproliferative effect of mAblO8 was potentiated when various antineoplastic drugs were added together with the anti-EGF-receptor antibodies (8) .
In the present study we examine the possibility of enhancing the antitumor effect of mAblO8 by conjugating it to an antineoplastic drug, doxorubicin. The drug was conjugated by means of periodate-oxidized dextran to the antibodies. We had previously shown that daunorubicin'conjugated to antibodies against rat a-fetoprotein was very effective in prolonging the survival time of intraperitoneally hepatomachallenged rats (9) . This work was recently successfully extended to subcutaneous hepatoma tumors that metastasize to the lungs with or without surgical resection of'the'subcutaneous tumor (10 (11) . The mAb were purified as described (8) .
Binding of Antibody to Doxorubicin. mAblO8 or antidinitrophenyl (DNP) mAb were linked to doxorubicin (lot 50432619, Farmitalia) through a dextran bridge, as reported (12) Labeling of the mAb was performed by the chloramine-T method (13) . KB cells (105 cells per well in 24-well plates, Nunc) were grown for 24 hr, washed with PBS, and incubated with different concentrations of either conjugated or native mAb for 1 hr at room temperature in the presence of 1251_ labeled mAb (=1.106 cpm/ml; 3.106 cpm/gg). The cells were then washed and solubilized in 0.5 NaOH, and the associated radioactivity was determined in a y counter (Kontron, Munchenstein, Switzerland). Concentrations of conjugated mAbs necessary to compete with binding of free labeled mAb were determined, and values at 50% competition were compared with those obtained by unconjugated mAb.
Drug Activity of the Conjugates. Drug activity was measured by the capacity of the conjugates to inhibit KB colony formation. KB cells were seeded in tissue culture dishes (50 x 15 mm2; Nunc) at 100 cells per ml and 2.5 ml per dish. After 16-24 hr the medium was replaced, and different concentrations of either free or mAb-conjugated doxorubicin were added for 15 min at 4°C. The cells were washed once with PBS and incubated for 14 days. The cultures were then washed with PBS, fixed with 4% (vol/vol) formaldehyde for 15 min, and stained with hematoxylin. The number of colonies formed (>25 cells) was then determined. In addition, we assayed the conjugates for the inhibition of [3H]thymidine incorporation as described (14) .
The Antitumor Activity of mAblO8-Dextran-Doxorubicin in Nude Mice. The antitumor activity of mAblO8-dextrandoxorubicin conjugates was studied on s.c. xenografts of the human epidermoid carcinoma in nude mice as described (8) .
Briefly, KB cells (0.5-1.106) were injected s.c. into nude mice; this injection produced tumors in 100% of the mice 10 days after cell implantation. Tumor weight was 0.6-1.3 g after 27-37 days, depending on the initial cell inoculum. Treatment was started 1 day after tumor transplantation by three i.v. injections at 3-to 4-day intervals. Each treatment group consisted of at least six animals. Tumor parameters were measured twice a week with a caliper, and the volume of a tumor was calculated according to the standard formula: tumor volume in mm3 = length x width x height. To validate volume measurements, correlation between tumor volume and tumor weight at death was assessed.
RESULTS
We have first examined the capacity of anti EGF-receptor antibodies (mAb1O8) conjugated with dextran-doxorubicin to bind to the EGF receptor of cultured KB cells. A displacement assay in which the conjugated antibodies were used to block the binding of 125I-labeled mAblO8 to cultured KB cells was used to determine binding specificity. Table 1 summarizes the binding properties of various mAb preparations containing different amounts of drug ranging from 10 to 92 doxorubicin molecules per mAb molecule. The drug was bound to the mAb through a bridge, and, therefore, no direct correlation between extent of substitution and preservation of antibody activity was found. The most-substituted mAb conjugate (drug-to-mAb molar ratio of 82:1) retained 65% of the original mAb binding activity. Highly substituted reduced conjugate (97:1 molar ratio) retained 55% of mAb-receptor binding activity.
The Effect of Conjugated mAblO8 on the Growth of Cultured KB Cells. The inhibition of KB-cell colony formation was used as a measure for drug activity in vitro and was determined by exposing cultured KB cells (250 in 2.5 ml) for 15 min at 4°C (Fig. 1) with either mAblO8-dextran-doxorubicin (experiment 3, 26:1 molar ratio of drug to mAb), anti-DNP-dextran-doxorubicin (same drug substitution), or free doxorubicin. The drug concentrations required for a 50% reduction in the number of KB cell colonies were 0.28, 0.47, and 0.15 ,g/ml, respectively. These results indicated that conjugated mAb were less potent than the drug alone, but more potent than doxorubicin attached to control anti-DNP antibodies.
,100 (8) . In the group treated with the specific mAb conjugate in which the drug bonds to the dextran were chemically reduced, dramatic reduction in the antitumor effect was seen ( Table 2 ). The group treated with this reduced conjugate showed no statistically significant difference from the placebo group and other controls. Fig. 2 (8); the mAbs concentrated and localized in the tumor mass. Thus, the mAb-mediated antitumor effect could conceivably be enhanced by conjugating the mAbs to doxorubicin, a drug widely used in solid-tumor chemotherapy despite its high toxicity.
Conjugates with doxorubicin were prepared successfully in our laboratory (9, 12, 14) , as well as by others (15, 16) . We report here the preparation of drug-mAb conjugates of high drug-to-mAb molar ratio, which specifically bind to the EGF receptor and exert cytotoxic effects on KB tumors in nude mice. The conjugate has an average molecular mass of -200 kDa, as revealed by sucrose-gradient centrifugation, indicating that the preparation mainly contains a monomeric form composed of three to five molecules of dextran per mAb molecule. Another group reported the use of dextran as a spacer for the construction of conjugates, reaching a drugto-antibody ratio of only 3.5-4, and they obtained a molecular mass of 1.5 x 106 for the antibody conjugates (15 When a conjugate with a higher degree of drug substitution was used (experiment 4), superior efficacy was seen over all control groups, including a mixture of mAb and dextrandoxorubicin. Evidently a high degree of drug substitution can compensate for the loss of mAb activity. Moreover, when a similar conjugate, containing reduced-Schiff base linkages, was used for bridging antibody to dextran, the conjugate was less effective, indicating that drug release at the tumor site did not occur. This last observation is consistent with the notion that internalization of the drug is necessary for efficient drug action. A recent report by Yang and Reisfeld (16) further supports this idea; they used antibodies to human melanomaassociated proteoglycan linked by means of an acid-sensitive linker, cis-aconitic anhydride, to doxorubicin. The potency of specific conjugates was explained by their stability at the intravascular pH, followed by endocytosis and cleavage in the more acidic environment of endosomes and lysosomes.
The accessibility of antibodies or drug-antibody conjugates to their target cells is a relevant variable affecting the efficacy of drug targeting. To assess this function we have checked the effect of the conjugates on KB tumor nodules in the lungs of nude mice. Preliminary results indicate that lung metastasis was also affected by the specific antibody conjugate.
From these results, it is evident that targeting of drugs to tumor-specific sites is feasible and that the use of an active antibody may contribute to the desirable anti-tumor effect of that conjugate.
